Trial Profile

A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Solithromycin (Primary) ; Solithromycin (Primary) ; Amoxicillin; Amoxicillin; Amoxicillin; Azithromycin; Ceftriaxone; Erythromycin; Erythromycin ethylsuccinate; Erythromycin lactobionate
Indications Community-acquired pneumonia
Focus Adverse reactions; Registrational
Sponsors Cempra Pharmaceuticals; Melinta Therapeutics

01 Jul 2022 Results published in the Pediatric Infectious Disease Journal
29 May 2018 Status changed from recruiting to discontinued as development not proceeding
06 Nov 2017 According to Melinta Therapeutics media release, Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com